LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it is seeking applicants for a new $100,000 U.S. research award to support the advancement of photopheresis and red cell exchange – two therapeutic areas with great promise for patient care.
“Fresenius Kabi along with its Fenwal subsidiary are committed to supporting innovative science that provides hope through the advancement of photopheresis and red cell exchange,” said William Cork, executive vice president and chief technology officer for the Fresenius Kabi Medical Devices division.
Interested applicants are encouraged to learn more about the Fresenius Kabi award, the eligibility criteria and conditions, and apply by visiting www.FreseniusKabiScience.com. The application deadline is Sunday, December 15, 2013.
Photopheresis therapy involves using advanced blood-separation techniques to introduce light-activated drugs to the blood, expose the blood to ultraviolet light outside the body, and return the treated blood to the patient. This is used today to treat rare cancers and immune disorders.
Red cell exchange involves removing and replacing a patient’s red cells using specialized blood-separation equipment and medicines. It is prescribed to help treat sickle cell disease and other conditions.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com) is a leading global health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients inside and outside the hospital. Fresenius Kabi products include intravenous specialty and generic medicines, infusion therapies, clinical nutrition and related medical devices. Within transfusion technologies, Fresenius Kabi offers products for whole blood collection and processing as well as for transfusion medicine and cell therapies. The company’s roots go back more than 100 years to the founding of its parent company, Fresenius SE, in Bad Homburg, Germany, where the company is headquartered today.
Acquired by Fresenius Kabi in December 2012, Fenwal (www.fenwalinc.com) is focused on improving transfusion medicine through expertise in blood separation, collection, filtration, storage and transfusion. Fenwal offers a broad range of products and services for the automated and manual collection of blood and blood components.
